Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Co-Occurring Alterations of ERBB2 Exon 20 Insertion in Non-Small Cell Lung Cancer (NSCLC) and the Potential Indicator of Response to Afatinib

Background: Human epidermal growth factor receptor 2 (ERBB2, HER-2) exon 20 insertion (ERBB2ex20ins) remains a refractory oncogenic driver in lung cancer. So far there is limited data showing the co-occurring mutation background of ERBB2ex20ins in Chinese lung cancer and its relationship with respon...

Full description

Bibliographic Details
Main Authors: Bo Yuan, Jun Zhao, Chengzhi Zhou, Xiumei Wang, Bo Zhu, Minglei Zhuo, Xilin Dong, Jiemei Feng, Cuihua Yi, Yunpeng Yang, Hua Zhang, Wangyan Zhou, Zhengtang Chen, Sheng Yang, Xinghao Ai, Kehe Chen, Xuefan Cui, Difa Liu, Chunmei Shi, Wei Wu, Yanjun Zhang, Lianpeng Chang, Jin Li, Rongrong Chen, Shuanying Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
ERBB2 exon 20 insertion
co-occurring alterations
afatinib
clonality status
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00729/full

Similar Items

Similar Items